Company intelligence / Profile preview

GlucoFit

Seoul, Seoul Special City, South Koreaieeexplore.ieee.org ↗

Ownership: Private
Development stage: Commercial

Overview

GlucoFit is an active healthcare technology startup founded in 2022 in Seoul, South Korea. The company provides an AI-powered digital platform to support individuals with diabetes through personalized analytics and therapy recommendations. It has raised $900K in seed funding from several venture investors. There is no evidence of clinical trial results as it is not developing drugs or biologics but rather offers a software-based solution for disease management.

Therapeutic areas: Endocrinology
Modalities: Device (digital health platform)
Industry: Digital Health Medical Devices

Drug pipeline

1 asset

Glucofit

Commercial

Indications: Diabetes, Prediabetes, Obesity, Metabolic disorders

Beyond the preview

Go deeper on GlucoFit.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GlucoFit.

Explore the full profile